{"protocolSection": {"identificationModule": {"nctId": "NCT03964220", "orgStudyIdInfo": {"id": "0205-0543"}, "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Impact of Tiotropium Add-on Therapy in Patients With Asthma", "officialTitle": "The Effectiveness of Tiotropium Add-on Therapy Using a Real-world Cohort of Patients With Asthma"}, "statusModule": {"statusVerifiedDate": "2020-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-03-15", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-09-20", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-09-20", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-05-24", "studyFirstSubmitQcDate": "2019-05-24", "studyFirstPostDateStruct": {"date": "2019-05-28", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-09-17", "resultsFirstSubmitQcDate": "2020-09-17", "resultsFirstPostDateStruct": {"date": "2020-10-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-10-13", "lastUpdatePostDateStruct": {"date": "2020-11-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "To evaluate the effectiveness of add on therapy with Tiotropium Respimat\u00ae compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy"}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 7857, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Patients with Asthma", "interventionNames": ["Drug: Tiotropium Respimat\u00ae", "Drug: Inhaled Corticosteroid/Long-acting beta-agonist"]}], "interventions": [{"type": "DRUG", "name": "Tiotropium Respimat\u00ae", "description": "Tiotropium Respimat\u00ae 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )", "armGroupLabels": ["Patients with Asthma"]}, {"type": "DRUG", "name": "Inhaled Corticosteroid/Long-acting beta-agonist", "description": "baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA", "armGroupLabels": ["Patients with Asthma"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Time to First Exacerbation", "description": "Exacerbations will be defined as either a hospitalization with a primary diagnosis of asthma, an emergency room (ER) visit with a primary diagnosis of asthma, an asthma exacerbation diagnosis recorded.", "timeFrame": "From baseline until end of follow-up, up to 3 years"}], "secondaryOutcomes": [{"measure": "Rate of Exacerbation at 6 Months and 1 Year of Follow-up", "description": "Exacerbation rate per 100 person-years. Follow-up period was from index date (date of the first prescription for Tiotropium Respimat\u00ae 1.25 mcg in Tio group; date of the first prescription from low to medium/high does or medium to high does or additional high-does of Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) for NonTio group).", "timeFrame": "At 6 month and 1 year of follow-up"}, {"measure": "Health Care Resource Utilization (HCRU) During Follow-up", "description": "Follow-up period was from index date (date of the first prescription for Tiotropium Respimat\u00ae 1.25 mcg in Tio group; date of the first prescription from low to medium/high does or medium to high does or additional high-does of Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) for NonTio group) and up to 3 years of study period.", "timeFrame": "During follow-up period, From baseline until end of follow-up, up to 3 years"}, {"measure": "Change in Lung Function (Forced Expiratory Volume in 1 Second (FEV1) Score) at Baseline and Follow up Period", "description": "Follow-up period was from index date (date of the first prescription for Tiotropium Respimat\u00ae 1.25 mcg in Tio group; date of the first prescription from low to medium/high does or medium to high does or additional high-does of Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) for NonTio group) and up to 3 years of study period. FEV1 score range from 0 to 100. Higher FEV1 score suggests normal lung function, while lower for dangerous. Only the descriptive statistics of FEV1 score were reported other than change of FEV1 score from baseline due to lack of enough data points.", "timeFrame": "From baseline until end of follow-up, up to 3 years"}, {"measure": "Change in Asthma Control Test (ACT) Score at Baseline and in the Follow up Period", "description": "Follow-up period was from index date (date of the first prescription for Tiotropium Respimat\u00ae 1.25 mcg in Tio group; date of the first prescription from low to medium/high does or medium to high does or additional high-does of Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) for NonTio group) and up to 3 years of study period. ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms not under control. Only the descriptive statistics of ACT score were reported other than change of ACT score from baseline due to lack of enough data points.", "timeFrame": "From baseline until end of follow-up, up to 3 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with least one asthma diagnosis in the inpatient setting or at least two separate instances of asthma diagnosis (separated by at least 30 days) recorded in the outpatient or emergency room setting will be included.\n* Patients will be required to be already on Inhaled Corticosteroid/Long-acting beta-agonist (ICS/LABA).\n* Patients will be required to have available records 12 months prior to the index date.\n\nExclusion Criteria:\n\n* Patients below the age of 6 years on the Inhaled Corticosteroid/Long-acting beta-agonist initiation (ICS/LABAi) date will be excluded.\n* Patients with a diagnosis of COPD at any time during the study period will be excluded.\n* Those who are on biologics at baseline will be removed.\n* After the PSM process, unmatched patients will be excluded.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "Asthmatics 6 years and above on ICS/LABA at baselineIMS Pharmetrics (IMS or Database I); EMRClaims+ (Database II)", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "eMax Health", "city": "White Plains", "state": "New York", "zip": "10601", "country": "United States", "geoPoint": {"lat": 41.03399, "lon": -73.76291}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Related Info", "url": "https://trials.boehringer-ingelheim.com/"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https:// trials.boehringer-ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed \"Document Sharing Agreement\". Also, Researchers can use the following link http://trials.boehringeringelheim. com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"], "timeFrame": "After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.", "accessCriteria": "For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.", "url": "https://trials.boehringer-ingelheim.com"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This study included asthma patients from two retrospective data sources (IMS Pharmetrics and EMRClaims+) after propensity score matching based on ICS/LABA dose on initiation date, demographics, Charlson Comorbidity index (CCI) score, specific comorbidities, medications and asthma control status.", "recruitmentDetails": "A retrospective cohort data analysis evaluated the effectiveness of add on therapy with Tiotropium Respimat\u00ae 1.25 microgram comparing to increasing the dose of Inhaled Corticosteroid (ICS) in patients with a diagnosis of Asthma and on ICS/Long-acting beta-agonist (LABA) therapy.", "groups": [{"id": "FG000", "title": "Tiotropium Respimat\u00ae (Tio Group)", "description": "1.25 microgram (mcg) of solution of inhalation of Tiotropium Respimat\u00ae added-on to Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) therapy.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}, {"id": "FG001", "title": "Inhaled Corticosteroid/Long-acting Beta-agonist (NonTio Group)", "description": "Low dose ICS/LABA to medium/high dose ICS/LABA or from baseline medium dose ICS/LABA to high dose ICS/LABA or an additional prescription/refill of high-dose ICS/LABA following the first prescription of baseline high dose ICS/LABA within the study period.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2619"}, {"groupId": "FG001", "numSubjects": "5238"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2619"}, {"groupId": "FG001", "numSubjects": "5238"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "This study included asthma patients from two retrospective data sources (IMS Pharmetrics and EMRClaims+) after propensity score matching based on ICS/LABA dose on initiation date, demographics, Charlson Comorbidity index (CCI) score, specific comorbidities, medications and asthma control status.", "groups": [{"id": "BG000", "title": "Tiotropium Respimat\u00ae (Tio Group)", "description": "1.25 microgram (mcg) of solution of inhalation of Tiotropium Respimat\u00ae added-on to Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) therapy.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}, {"id": "BG001", "title": "Inhaled Corticosteroid/Long-acting Beta-agonist (NonTio Group)", "description": "Low dose ICS/LABA to medium/high dose ICS/LABA or from baseline medium dose ICS/LABA to high dose ICS/LABA or an additional prescription/refill of high-dose ICS/LABA following the first prescription of baseline high dose ICS/LABA within the study period.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2619"}, {"groupId": "BG001", "value": "5238"}, {"groupId": "BG002", "value": "7857"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2619"}, {"groupId": "BG001", "value": "5238"}, {"groupId": "BG002", "value": "7857"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "45.12", "spread": "15.38"}, {"groupId": "BG001", "value": "44.77", "spread": "15.43"}, {"groupId": "BG002", "value": "44.89", "spread": "15.41"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2619"}, {"groupId": "BG001", "value": "5238"}, {"groupId": "BG002", "value": "7857"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1802"}, {"groupId": "BG001", "value": "3576"}, {"groupId": "BG002", "value": "5378"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "817"}, {"groupId": "BG001", "value": "1662"}, {"groupId": "BG002", "value": "2479"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Time to First Exacerbation", "description": "Exacerbations will be defined as either a hospitalization with a primary diagnosis of asthma, an emergency room (ER) visit with a primary diagnosis of asthma, an asthma exacerbation diagnosis recorded.", "populationDescription": "This study included asthma patients from two retrospective data sources (IMS Pharmetrics and EMRClaims+) after propensity score matching based on ICS/LABA dose on initiation date, demographics, Charlson Comorbidity index (CCI) score, specific comorbidities, medications and asthma control status.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "From baseline until end of follow-up, up to 3 years", "groups": [{"id": "OG000", "title": "Tiotropium Respimat\u00ae (Tio Group)", "description": "1.25 microgram (mcg) of solution of inhalation of Tiotropium Respimat\u00ae added-on to Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) therapy.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}, {"id": "OG001", "title": "Inhaled Corticosteroid/Long-acting Beta-agonist (NonTio Group)", "description": "Low dose ICS/LABA to medium/high dose ICS/LABA or from baseline medium dose ICS/LABA to high dose ICS/LABA or an additional prescription/refill of high-dose ICS/LABA following the first prescription of baseline high dose ICS/LABA within the study period.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2619"}, {"groupId": "OG001", "value": "5238"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "340.656", "spread": "428.061"}, {"groupId": "OG001", "value": "123.151", "spread": "152.600"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The time to first exacerbation was analysis using Cox Proportional Hazards model with group status as the only independent variable assessing the risk of exacerbation across Tio and NonTio groups.", "nonInferiorityType": "OTHER", "pValue": "0.044", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.427", "ciUpperLimit": "0.990"}]}, {"type": "SECONDARY", "title": "Rate of Exacerbation at 6 Months and 1 Year of Follow-up", "description": "Exacerbation rate per 100 person-years. Follow-up period was from index date (date of the first prescription for Tiotropium Respimat\u00ae 1.25 mcg in Tio group; date of the first prescription from low to medium/high does or medium to high does or additional high-does of Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) for NonTio group).", "populationDescription": "This study included asthma patients from two retrospective data sources (IMS Pharmetrics and EMRClaims+) after propensity score matching based on ICS/LABA dose on initiation date, demographics, Charlson Comorbidity index (CCI) score, specific comorbidities, medications and asthma control status.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events per 100 person-years", "timeFrame": "At 6 month and 1 year of follow-up", "groups": [{"id": "OG000", "title": "Tiotropium Respimat\u00ae (Tio Group)", "description": "1.25 microgram (mcg) of solution of inhalation of Tiotropium Respimat\u00ae added-on to Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) therapy.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}, {"id": "OG001", "title": "Inhaled Corticosteroid/Long-acting Beta-agonist (NonTio Group)", "description": "Low dose ICS/LABA to medium/high dose ICS/LABA or from baseline medium dose ICS/LABA to high dose ICS/LABA or an additional prescription/refill of high-dose ICS/LABA following the first prescription of baseline high dose ICS/LABA within the study period.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2619"}, {"groupId": "OG001", "value": "5238"}]}], "classes": [{"title": "At 6 months of follow-up", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.40"}, {"groupId": "OG001", "value": "116.07"}]}]}, {"title": "At 1 year of follow-up", "categories": [{"measurements": [{"groupId": "OG000", "value": "15.65"}, {"groupId": "OG001", "value": "57.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis for the rate of exacerbation between Tio and NonTio groups within 6 months of follow-up.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "statisticalMethod": "Negative binomial regression"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis for the rate of exacerbation between Tio and NonTio groups within 1 year of follow-up.", "nonInferiorityType": "OTHER", "pValue": "< 0.0001", "statisticalMethod": "Negative binomial regression"}]}, {"type": "SECONDARY", "title": "Health Care Resource Utilization (HCRU) During Follow-up", "description": "Follow-up period was from index date (date of the first prescription for Tiotropium Respimat\u00ae 1.25 mcg in Tio group; date of the first prescription from low to medium/high does or medium to high does or additional high-does of Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) for NonTio group) and up to 3 years of study period.", "populationDescription": "This study included asthma patients from two retrospective data sources (IMS Pharmetrics and EMRClaims+) after propensity score matching based on ICS/LABA dose on initiation date, demographics, Charlson Comorbidity index (CCI) score, specific comorbidities, medications and asthma control status.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events per 100 person-years", "timeFrame": "During follow-up period, From baseline until end of follow-up, up to 3 years", "groups": [{"id": "OG000", "title": "Tiotropium Respimat\u00ae (Tio Group)", "description": "1.25 microgram (mcg) of solution of inhalation of Tiotropium Respimat\u00ae added-on to Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) therapy.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}, {"id": "OG001", "title": "Inhaled Corticosteroid/Long-acting Beta-agonist (NonTio Group)", "description": "Low dose ICS/LABA to medium/high dose ICS/LABA or from baseline medium dose ICS/LABA to high dose ICS/LABA or an additional prescription/refill of high-dose ICS/LABA following the first prescription of baseline high dose ICS/LABA within the study period.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2619"}, {"groupId": "OG001", "value": "5238"}]}], "classes": [{"title": "Hospitalization (all cause)", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.97"}, {"groupId": "OG001", "value": "46.51"}]}]}, {"title": "Hospitalization (asthma related)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.89"}, {"groupId": "OG001", "value": "20.27"}]}]}, {"title": "Emergency room (ER) visit (all cause)", "categories": [{"measurements": [{"groupId": "OG000", "value": "45.00"}, {"groupId": "OG001", "value": "84.67"}]}]}, {"title": "ER visit (asthma related)", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.23"}, {"groupId": "OG001", "value": "47.70"}]}]}, {"title": "Outpatient (OP) visit (all cause)", "categories": [{"measurements": [{"groupId": "OG000", "value": "206.92"}, {"groupId": "OG001", "value": "232.55"}]}]}, {"title": "OP visit (asthma related)", "categories": [{"measurements": [{"groupId": "OG000", "value": "133.06"}, {"groupId": "OG001", "value": "158.61"}]}]}]}, {"type": "SECONDARY", "title": "Change in Lung Function (Forced Expiratory Volume in 1 Second (FEV1) Score) at Baseline and Follow up Period", "description": "Follow-up period was from index date (date of the first prescription for Tiotropium Respimat\u00ae 1.25 mcg in Tio group; date of the first prescription from low to medium/high does or medium to high does or additional high-does of Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) for NonTio group) and up to 3 years of study period. FEV1 score range from 0 to 100. Higher FEV1 score suggests normal lung function, while lower for dangerous. Only the descriptive statistics of FEV1 score were reported other than change of FEV1 score from baseline due to lack of enough data points.", "populationDescription": "This study included asthma patients from two retrospective data sources (IMS Pharmetrics and EMRClaims+) after propensity score matching based on ICS/LABA dose on initiation date, demographics, CCI score, specific comorbidities, medications and asthma control status. Analysis conducted with participants with non-missing endpoint results.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "From baseline until end of follow-up, up to 3 years", "groups": [{"id": "OG000", "title": "Tiotropium Respimat\u00ae (Tio Group)", "description": "1.25 microgram (mcg) of solution of inhalation of Tiotropium Respimat\u00ae added-on to Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) therapy.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}, {"id": "OG001", "title": "Inhaled Corticosteroid/Long-acting Beta-agonist (NonTio Group)", "description": "Low dose ICS/LABA to medium/high dose ICS/LABA or from baseline medium dose ICS/LABA to high dose ICS/LABA or an additional prescription/refill of high-dose ICS/LABA following the first prescription of baseline high dose ICS/LABA within the study period.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "77.77", "spread": "20.16"}, {"groupId": "OG001", "value": "85.69", "spread": "20.77"}]}]}]}, {"type": "SECONDARY", "title": "Change in Asthma Control Test (ACT) Score at Baseline and in the Follow up Period", "description": "Follow-up period was from index date (date of the first prescription for Tiotropium Respimat\u00ae 1.25 mcg in Tio group; date of the first prescription from low to medium/high does or medium to high does or additional high-does of Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) for NonTio group) and up to 3 years of study period. ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms not under control. Only the descriptive statistics of ACT score were reported other than change of ACT score from baseline due to lack of enough data points.", "populationDescription": "This study included asthma patients from two retrospective data sources (IMS Pharmetrics and EMRClaims+) after propensity score matching based on ICS/LABA dose on initiation date, demographics, CCI score, specific comorbidities, medications and asthma control status. Analysis conducted with participants with non-missing endpoint results.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "From baseline until end of follow-up, up to 3 years", "groups": [{"id": "OG000", "title": "Tiotropium Respimat\u00ae (Tio Group)", "description": "1.25 microgram (mcg) of solution of inhalation of Tiotropium Respimat\u00ae added-on to Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) therapy.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}, {"id": "OG001", "title": "Inhaled Corticosteroid/Long-acting Beta-agonist (NonTio Group)", "description": "Low dose ICS/LABA to medium/high dose ICS/LABA or from baseline medium dose ICS/LABA to high dose ICS/LABA or an additional prescription/refill of high-dose ICS/LABA following the first prescription of baseline high dose ICS/LABA within the study period.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg))."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.65", "spread": "7.0"}, {"groupId": "OG001", "value": "16.16", "spread": "5.3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse event information was not applicable for this study", "description": "As this is a non-interventional study with secondary use of data retrieved from IMS Pharmetrics and EMRClaims+\u00ae database, safety monitoring and safety reporting on an individual case level is not applicable.", "eventGroups": [{"id": "EG000", "title": "Tiotropium Respimat\u00ae (Tio Group)", "description": "1.25 microgram (mcg) of solution of inhalation of Tiotropium Respimat\u00ae added-on to Inhaled Corticosteroid (ICS)/long-acting beta-agonists (LABA) therapy.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg)).", "deathsNumAffected": 0, "deathsNumAtRisk": 0, "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}, {"id": "EG001", "title": "Inhaled Corticosteroid/Long-acting Beta-agonist (NonTio Group)", "description": "Low dose ICS/LABA to medium/high dose ICS/LABA or from baseline medium dose ICS/LABA to high dose ICS/LABA or an additional prescription/refill of high-dose ICS/LABA following the first prescription of baseline high dose ICS/LABA within the study period.\n\nAdvair Diskus, Advair HFA, AirDuo, Breo, Dulera or Symbicort were used for the ICS/LABA therapy from low dose (Advair Diskus (100mcg), Advair HFA (45mcg), AirDuo (55mcg), Breo (100mcg), Dulera (100mcg), Symbicort (80mcg)), to medium dose (Advair Diskus (250mcg), Advair HFA (115mcg), AirDuo (113mcg)) and high dose (Advair Diskus (500mcg), Advair HFA (230mcg), AirDuo (232mcg), Breo (200mcg), Dulera (200mcg), Symbicort (160mcg)).", "deathsNumAffected": 0, "deathsNumAtRisk": 0, "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.\n\nInvestigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.\n\nBI may request a delay of the publication in order to protect BI's intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2019-02-18", "uploadDate": "2020-09-03T04:13", "filename": "Prot_SAP_000.pdf", "size": 299484}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069447", "term": "Tiotropium Bromide"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000010276", "term": "Parasympatholytics"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M416", "name": "Tiotropium Bromide", "asFound": "Melanoma", "relevance": "HIGH"}, {"id": "M5241", "name": "Bromides", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M13189", "name": "Parasympatholytics", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}]}}, "hasResults": true}